Breast (Aug 2024)
The features of male breast cancer in China: A real-world study
- Yuxuan Gao,
- Mengmeng Zhang,
- Gang Sun,
- Li Ma,
- Jianyun Nie,
- Zhongyu Yuan,
- Zhenzhen Liu,
- Yali Cao,
- Jianbin Li,
- Qiang Liu,
- Songqing Ye,
- Bo Chen,
- Yuhua Song,
- Kun Wang,
- Yu Ren,
- Guolin Ye,
- Ling Xu,
- Shu Liu,
- Qianjun Chen,
- Weiwen Li,
- Xinxin Chen,
- Peifen Fu,
- Wei Wei,
- Baoliang Guo,
- Hebing Wang,
- Zhenhai Cai,
- Caiwen Du,
- Zhiyong Wu,
- Xiaoming Zha,
- Heng Huang,
- Juan Xu,
- Chenglei Zhang,
- Yingying Shi,
- Ting Liu,
- Sihua Liu,
- Zefei Jiang,
- Ying Lin
Affiliations
- Yuxuan Gao
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Mengmeng Zhang
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Gang Sun
- Department of Breast and Thyroid Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China
- Li Ma
- Department of Breast Surgery, Hebei Provincial Tumor Hospital, Shijiazhuang, China
- Jianyun Nie
- Breast Cancer Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China
- Zhongyu Yuan
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Zhenzhen Liu
- Department of Breast Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
- Yali Cao
- Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Nanchang, China
- Jianbin Li
- The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
- Qiang Liu
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
- Songqing Ye
- Department of Tumor Surgery, Fujian Provincial Hospital, Fuzhou, China
- Bo Chen
- The Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China
- Yuhua Song
- Breast Center B Ward, The Affiliated Hospital of Qingdao University, Qingdao, China
- Kun Wang
- Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
- Yu Ren
- Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Guolin Ye
- Department of Breast Surgery, The First People's Hospital of Foshan, Foshan, China
- Ling Xu
- Department of Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China
- Shu Liu
- Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- Qianjun Chen
- Department of Breast Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
- Weiwen Li
- Department of Breast, Jiangmen Central Hospital, Jiangmen, China
- Xinxin Chen
- Department of Breast Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
- Peifen Fu
- Department of Breast Surgery, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
- Wei Wei
- Peking University Shenzhen Hospital, Shenzhen, China
- Baoliang Guo
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin City, China
- Hebing Wang
- Department of Breast Surgery, Affiliated Sanming First Hospital of Fujian Medical University, Sanming, China
- Zhenhai Cai
- Jieyang People's Hospital, Jieyang, China
- Caiwen Du
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
- Zhiyong Wu
- Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China
- Xiaoming Zha
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Heng Huang
- Department of Breast Oncology, Lianjiang Pepole's Hospital, Lianjiang, China
- Juan Xu
- Guangdong Women and Children Hospital, Guangzhou, China
- Chenglei Zhang
- Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China
- Yingying Shi
- Department of Breast Disease, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai City, China
- Ting Liu
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Sihua Liu
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Zefei Jiang
- The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; Corresponding author. 8 Dongdajie, Fengtai District, Beijing, China.
- Ying Lin
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Corresponding author. Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, China.
- Journal volume & issue
-
Vol. 76
p. 103762
Abstract
Background: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. This study aims to explore the features of Chinese MBC patients comprehensively. Methods: We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients. Results: In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %–88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175). Conclusion: As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
